170 related articles for article (PubMed ID: 25583594)
21. A novel GLA mutation in a Fabry family with glucose-6-phosphate dehydrogenase deficiency.
Pisani A; Visciano B; Russo R; Mozzillo GR; Porto C; De Maggio I; Russo R; Pontarelli G; Villani GR; Cianciaruso B; Di Natale P
J Nephrol; 2012; 25(4):582-5. PubMed ID: 22307442
[TBL] [Abstract][Full Text] [Related]
22. Prominent regression of corneal deposits in Fabry disease 16 years after initiation of enzyme replacement therapy.
Koh S; Sakai N; Maeda N; Nishida K
Acta Ophthalmol; 2018 Mar; 96(2):e255-e256. PubMed ID: 28834375
[No Abstract] [Full Text] [Related]
23. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
[TBL] [Abstract][Full Text] [Related]
24. Fabry disease exhibiting recurrent stroke and persistent inflammation.
Kikumoto Y; Kai Y; Morinaga H; Iga-Murahashi M; Matsuyama M; Sasaki T; Maruyama H; Shimotori M; Makino H; Sugiyama H; Okayama A
Intern Med; 2010; 49(20):2247-52. PubMed ID: 20962444
[TBL] [Abstract][Full Text] [Related]
25. Petechial-like lesions, eye abnormalities, and albuminuria in a young boy.
Roganović J
Pediatr Dermatol; 2011; 28(6):727-728. PubMed ID: 22082470
[No Abstract] [Full Text] [Related]
26. [Fabry disease--diagnostic guideline].
Constantin T; Rákóczi E; Ponyi A; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Csikós M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G;
Orv Hetil; 2010 Feb; 151(7):243-9. PubMed ID: 20133243
[TBL] [Abstract][Full Text] [Related]
27. Fabry disease in an oligosymptomatic male.
Altarescu G; Elstein D
Isr Med Assoc J; 2011 Mar; 13(3):191-2. PubMed ID: 21608346
[No Abstract] [Full Text] [Related]
28. [A case of Anderson-Fabry disease: a multidisciplinary approach for diagnosis and follow up].
Zito A; De Pascalis A; Armeni A; Ria P; Barbarini L; Caggiula M; My F; Barbarini S; Trianni G; Napoli M
G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234233
[TBL] [Abstract][Full Text] [Related]
29. [Priapism: a severe paediatric complication of Fabry disease].
Labarthe F; de Bodman C; Maruani A; Szwarc C; Froissart R; Lorette G; Lardy H
Rev Med Interne; 2010 Dec; 31 Suppl 2():S217-9. PubMed ID: 21211667
[TBL] [Abstract][Full Text] [Related]
30. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease.
Auray-Blais C; Cyr D; Ntwari A; West ML; Cox-Brinkman J; Bichet DG; Germain DP; Laframboise R; Melançon SB; Stockley T; Clarke JT; Drouin R
Mol Genet Metab; 2008 Mar; 93(3):331-40. PubMed ID: 18023222
[TBL] [Abstract][Full Text] [Related]
31. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
[TBL] [Abstract][Full Text] [Related]
32. [Consensus for the study and treatment of Fabry disease. GETER Foundation].
García de Lorenzo A;
Med Clin (Barc); 2011 Jul; 137(4):178-83. PubMed ID: 21529855
[No Abstract] [Full Text] [Related]
33. Letter regarding Brouns et Al, Baptista et Al, and Wozniak et Al.
Lidove O; Joly D; Touzé E
Stroke; 2011 Jan; 42(1):e4-5; author reply e6-7. PubMed ID: 21148443
[No Abstract] [Full Text] [Related]
34. Anderson-Fabry disease.
Di Toro A; Favalli V; Arbustini E
J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e1-e5. PubMed ID: 29538136
[No Abstract] [Full Text] [Related]
35. The Fabry cardiomyopathy: models for the cardiologist.
Weidemann F; Niemann M; Warnock DG; Ertl G; Wanner C
Annu Rev Med; 2011; 62():59-67. PubMed ID: 21090963
[TBL] [Abstract][Full Text] [Related]
36. [Intravenous lidocaine as treatment for the painful episodes in Fabry's disease].
Politei JM
Rev Neurol; 2009 Aug 1-15; 49(3):166-7. PubMed ID: 19621314
[No Abstract] [Full Text] [Related]
37. [CME. Fabry disease: rare but not to be missed].
Steinack C; Gaspert A; Kovacs R; Nowak A
Praxis (Bern 1994); 2015 Jul; 104(14):719-29. PubMed ID: 26135721
[No Abstract] [Full Text] [Related]
38. Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature.
Thurberg BL; Politei JM
Hum Pathol; 2012 Apr; 43(4):610-4. PubMed ID: 22078290
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of alpha-galactosidase A upregulates CD77: functional impact for Fabry nephropathy.
Thomaidis T; Relle M; Golbas M; Brochhausen C; Galle PR; Beck M; Schwarting A
Kidney Int; 2009 Feb; 75(4):399-407. PubMed ID: 19037253
[TBL] [Abstract][Full Text] [Related]
40. De novo Diagnosis of Fabry Disease among Italian Adults with Acute Ischemic Stroke or Transient Ischemic Attack.
Romani I; Borsini W; Nencini P; Morrone A; Ferri L; Frusconi S; Donadio VA; Liguori R; Donati MA; Falconi S; Pracucci G; Inzitari D
J Stroke Cerebrovasc Dis; 2015 Nov; 24(11):2588-95. PubMed ID: 26298600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
